MisophoniaNCT06960083
Transcranial Magnetic Stimulation in Misophonia
A study testing Transcranial Magnetic Stimulation (TMS) in people with Misophonia, run by Icahn School of Medicine at Mount Sinai at 1 site in United States.
Trial summary
The purpose of the project is to assess the efficacy of parietal transcranial magnetic stimulation in misophonia. N=60 participants will undergo two transcranial magnetic stimulation sessions: one inhibitory and another excitatory. During both sessions, the parietal region will be stimulated. Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Misophonia
- What is being tested?
- Transcranial Magnetic Stimulation (TMS)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Sep 2025to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Hypersensitive to presence of a specific sound, which may be accompanied by irritation, anger/outbursts, or fear.
- Must be between the ages of 18 - 55.
- Must be fluent in English since the study's instructions, surveys, and tasks will be in English.
Who cannot join
- Epilepsy or previous episode of convulsion or seizure.
- Previous episode of fainting spell or syncope.
- Head trauma.
- Hearing problems.
- Cochlear implant.
- Metal in the brain, skull, or anywhere else in the body (e.g., splinters, fragments, clips, etc.).
Show all 13Show fewer
- Implanted neurostimulator (e.g., DBS, epidural/subdural, VNS).
- Presence of cardiac pacemaker or intracardiac lines.
- Presence of medication infusion device.
- Use of pro-convulsant or epileptogenic medications.
- Pregnancy. The risks associated with TMS exposure during gestation have not been studied extensively. We wish to safeguard the health of potential participants and their children.
- Lactation. The risks associated with TMS during lactation and its effects on infant development have not been studied. We wish to safeguard the health of potential participants and their children.
- Presence of Mania, Psychosis, Antisocial Personality Disorder, Borderline Personality Disorder, and Suicidal Ideation.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Mount Sinai West
New York, New York, 10022
Daniela Schiller, PhD, (212) 824-8977, daniela.schiller@mssm.edu
Martijn Figee, MD, PhD, martijn.figee@mssm.edu
About this study
Official title: A Transcranial Magnetic Stimulation Approach to Treat Misophonia
The purpose of the project is to assess the efficacy of parietal transcranial magnetic stimulation in misophonia. N=60 participants will undergo two transcranial magnetic stimulation sessions: one inhibitory and another excitatory. During both sessions, the parietal region will be stimulated. Participants will perform computerized tasks immediately before and after the stimulation, while EEG, heart rate, and skin temperature will be recorded. These recordings will be used to assess if TMS can be used to improve tolerance to misophonia triggers.
- Conditions
- Misophonia
- Being tested
- Transcranial Magnetic Stimulation (TMS)
- Keywords
- Misophonia, Transcranial Magnetic Stimulation, Crossover trial, Single session, EEG
- Medical subject headings
- misophonia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transcranial Magnetic Stimulation (TMS)Other
Transcranial Magnetic Stimulation (TMS) is an FDA-approved non-invasive brain stimulation technology. It is currently used for treating depression. Applications to other disorders such as OCD and anxiety using TMS are currently under investigation. TMS will be administered for 25 minutes.
| Study group | Role | What they receive |
|---|---|---|
| Inhibitory-Excitatory (IE) then Excitatory-Inhibitory (EI) | Active comparator | Participants in this group will receive an inhibitory TMS in the first session and an excitatory TMS in the second session. The two sessions will be separated by 72 hours. Receives: Other: Transcranial Magnetic Stimulation (TMS) |
| Excitatory-Inhibitory (EI) then Inhibitory-Excitatory (IE) | Active comparator | Participants in this group will receive an excitatory TMS in the first session and an inhibitory TMS in the second session. The two sessions will be separated by 72 hours. Receives: Other: Transcranial Magnetic Stimulation (TMS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Unpleasantness Rating Scale
Participants will be presented with a slider with extremes labelled as extremely unpleasant and extremely pleasant. Ratings will be provided for audio clips and visual cues. Full scale from 0-100, higher score indicates more unpleasantness
Measured: after each session, 72 hours apart (each session is 2 hours)
Secondary outcomes (6)
Heart Rate
The heart rate (number of beats per minute) will be measured using a wristwatch worn by the participant.
Measured: after each session, 72 hours apart (each session is 2 hours)
Skin Conductance Response
Skin conductance, a measure capturing the amount of sweat, will be measured using a wristwatch worn by the participant.
Measured: after each session, 72 hours apart (each session is 2 hours)
EEG P1-N1-P2 Complex Peak Amplitude
Amplitude (microvolts) of P1, N1, and P2 peaks measured in the parietal region
Measured: after each session, 72 hours apart (each session is 2 hours)
EEG P1-N1-P2 Complex Peak Latency
Latency (milliseconds) of P1, N1, and P2 peaks measured in the parietal region
Measured: after each session, 72 hours apart (each session is 2 hours)
EEG Frequency Band Amplitude
Amplitude (decibel) in theta (4-8 Hz), alpha (8-13 Hz), and beta (13-30 Hz) frequency bands in the parietal region
Measured: after each session, 72 hours apart (each session is 2 hours)
EEG Frequency Band Inter-Trial Coherence
Coherence (unitless) across trials in theta (4-8 Hz), alpha (8-13 Hz), and beta (13-30 Hz) frequency bands in the parietal region
Measured: after each session, 72 hours apart (each session is 2 hours)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 May 2025
- Study start2 Sep 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MisophoniaStudies of the same condition, open and under way.
- More trials run by Icahn School of Medicine at Mount SinaiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Participants will undergo two sessions of TMS, one inhibitory and another excitatory. The immediate changes resulting from both will be measured and compared.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Daniela Schiller, Icahn School of Medicine at Mount Sinai
- Investigators
- Daniela Schiller, PhD, Principal investigator, Icahn School of Medicine at Mount Sinai
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06960083
- Sponsor's protocol ID
- STUDY-24-00527
- Other IDs
- 24-0489-00001
- Status last verified
- Jul 2026
- First submitted
- 14 Apr 2025
- Last updated
- 15 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All of the individual participant data collected during the trial, after deidentification.
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Transcranial Magnetic Stimulation Approach to Treat Misophonia
- ClinicalTrials.gov ID
- NCT06960083
- Acronym / sponsor ID
- STUDY-24-00527
- Conditions
- Misophonia
- Keywords
- Misophonia, Transcranial Magnetic Stimulation, Crossover trial, Single session, EEG
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Icahn School of Medicine at Mount SinaiUniversity, hospital or other
- Study start
- 2 Sep 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 7 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the project is to assess the efficacy of parietal transcranial magnetic stimulation in misophonia. N=60 participants will undergo two transcranial magnetic stimulation sessions: one inhibitory and another excitatory. During both sessions, the parietal region will be stimulated. Participants will perform computerized tasks immediately before and after the stimulation, while EEG, heart rate, and skin temperature will be recorded. These recordings will be used to assess if TMS can be used to improve tolerance to misophonia triggers.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Participants will undergo two sessions of TMS, one inhibitory and another excitatory. The immediate changes resulting from both will be measured and compared.
| Arm | Type | Receives |
|---|---|---|
| Inhibitory-Excitatory (IE) then Excitatory-Inhibitory (EI) | Active comparator | Other: Transcranial Magnetic Stimulation (TMS)Participants in this group will receive an inhibitory TMS in the first session and an excitatory TMS in the second session. The two sessions will be separated by 72 hours. |
| Excitatory-Inhibitory (EI) then Inhibitory-Excitatory (IE) | Active comparator | Other: Transcranial Magnetic Stimulation (TMS)Participants in this group will receive an excitatory TMS in the first session and an inhibitory TMS in the second session. The two sessions will be separated by 72 hours. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Hypersensitive to presence of a specific sound, which may be accompanied by irritation, anger/outbursts, or fear.
- Must be between the ages of 18 - 55.
- Must be fluent in English since the study's instructions, surveys, and tasks will be in English.
Key exclusion criteria (13 listed)
- Epilepsy or previous episode of convulsion or seizure.
- Previous episode of fainting spell or syncope.
- Head trauma.
- Hearing problems.
- Cochlear implant.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transcranial Magnetic Stimulation (TMS)Transcranial Magnetic Stimulation (TMS) is an FDA-approved non-invasive brain stimulation technology. It is currently used for treating depression. Applications to other disorders such as OCD and anxiety using TMS are currently under investigation. TMS will be administered for 25 minutes. | Other | Excitatory-Inhibitory (EI) then Inhibitory-Excitatory (IE), Inhibitory-Excitatory (IE) then Excitatory-Inhibitory (EI) |
Primary outcome
Unpleasantness Rating Scale
Time frame: after each session, 72 hours apart (each session is 2 hours)
Participants will be presented with a slider with extremes labelled as extremely unpleasant and extremely pleasant. Ratings will be provided for audio clips and visual cues. Full scale from 0-100, higher score indicates more unpleasantness
6 secondary outcomes
Heart Rate
Time frame: after each session, 72 hours apart (each session is 2 hours)
Skin Conductance Response
Time frame: after each session, 72 hours apart (each session is 2 hours)
EEG P1-N1-P2 Complex Peak Amplitude
Time frame: after each session, 72 hours apart (each session is 2 hours)
EEG P1-N1-P2 Complex Peak Latency
Time frame: after each session, 72 hours apart (each session is 2 hours)
EEG Frequency Band Amplitude
Time frame: after each session, 72 hours apart (each session is 2 hours)
EEG Frequency Band Inter-Trial Coherence
Time frame: after each session, 72 hours apart (each session is 2 hours)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2026.
- Individual participant dataSharing planned: Yes. All of the individual participant data collected during the trial, after deidentification.
Related trials for Misophonia
Not yet recruitingObservational study
Pain, Central Sensitization, and Misophonia in Lipedema
Lipedema
Not yet recruiting
Effectiveness of a Mindfulness-Based Cognitive Behavioral Mobile Intervention for Misophonia
Misophonia, Misophonia Treatment
RecruitingObservational study
Prevalence of Misophonia in Turkish High School Students
Misophonia
RecruitingEarly Phase 1
Propranolol for Misophonia
Misophonia, Propanolol
Recruiting
Mindfulness Application Effects on Mental Health Symptoms in Children With Severe Tinnitus and Misophonia
Tinnitus, Misophonia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Daniela Schiller, PhD principal investigator
Icahn School of Medicine at Mount Sinai
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Transcranial Magnetic Stimulation (TMS) in people with Misophonia, run by Icahn School of Medicine at Mount Sinai at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Shama Patel (347-670-4878, shama.patel@mssm.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Unpleasantness Rating Scale (time frame: after each session, 72 hours apart (each session is 2 hours)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026.